Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Kyverna Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results

Advancing first-to-market autoimmune CAR T opportunity in stiff person syndrome (SPS) with key launch preparation activities underway; BLA submission anticipated in 1H 2026

Kyverna Therapeutics Appoints Biotech Leaders Sravan Emany and Andrew Miller to Board of Directors

Sravan Emany brings capital markets and commercial-stage, rare disease expertise as the Company advances towards commercialization

Kyverna Therapeutics Appoints Mayo Pujols as Chief Technology Officer

EMERYVILLE, Calif., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a clinical stage biopharmaceutical company developing cell therapies for patients with autoimmune diseases, today announced the appointment of Mayo Pujols as its Chief Technology Officer (CTO), effective February 9, 2026.

Kyverna Therapeutics Provides Corporate Update and Outlines 2026 Strategic Priorities at the J.P. Morgan Healthcare Conference

Advancing valuable commercial opportunity in stiff person syndrome (SPS) following landmark registrational data; Biologics License Application (BLA) submission anticipated in 1H 2026  First patient enrolled in registrational Phase 3 trial in generalized myasthenia gravis (gMG) Completed follow-on offering extends cash runway into 2028, expected to fully fund SPS BLA filing, commercial launch, and Phase 3 gMG trial Kyverna Board member, Christi Shaw, appointed as Executive Chairperson, further bolstering Company's CAR T commercialization experience; Ian Clark, former Chairperson, to remain on Board EMERYVILLE, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (Kyverna, Nasdaq: KYTX), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, provided today a corporate update and outlined its strategic priorities for 2026.